313 related articles for article (PubMed ID: 29074161)
1. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
Scott IU; Figueroa MJ; Oden NL; Ip MS; Blodi BA; VanVeldhuisen PC;
Am J Ophthalmol; 2017 Dec; 184():147-156. PubMed ID: 29074161
[TBL] [Abstract][Full Text] [Related]
2. SCORE2 Report 2: Study Design and Baseline Characteristics.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
[TBL] [Abstract][Full Text] [Related]
3. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
4. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
[TBL] [Abstract][Full Text] [Related]
5. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
[TBL] [Abstract][Full Text] [Related]
6. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
[TBL] [Abstract][Full Text] [Related]
7. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
[TBL] [Abstract][Full Text] [Related]
9. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
Ophthalmology; 2023 Oct; 130(10):1066-1072. PubMed ID: 37220815
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
Kymes SM; Oden NL; VanVeldhuisen PC; Scott IU; Ip MS; Blodi BA; King J;
JAMA Ophthalmol; 2023 Jun; 141(6):554-561. PubMed ID: 37166820
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Barton F; Oden NL; Ip MS; Blodi BA; Worrall M; Fish GE;
JAMA Ophthalmol; 2019 Aug; 137(8):932-938. PubMed ID: 31169862
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
13. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.
Hendrick A; VanVeldhuisen PC; Scott IU; King J; Blodi BA; Ip MS; Khurana RN; Oden NL;
Am J Ophthalmol; 2021 Feb; 222():185-193. PubMed ID: 32828880
[TBL] [Abstract][Full Text] [Related]
14. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
[TBL] [Abstract][Full Text] [Related]
15. OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
Au A; Ip M; Blodi BA; Scott IU; Oden NL; Van Veldhuisen PC; Sarraf D
Am J Ophthalmol; 2023 Dec; 256():55-62. PubMed ID: 37544495
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
17. SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1491-1500. PubMed ID: 34842984
[TBL] [Abstract][Full Text] [Related]
18. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
Etheridge T; Blodi B; Oden N; Van Veldhuisen P; Scott IU; Ip MS; Mititelu M; Domalpally A
Ophthalmol Retina; 2021 Oct; 5(10):991-998. PubMed ID: 33373715
[TBL] [Abstract][Full Text] [Related]
19. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
